June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Retrospective analysis of the common uses of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in clinical practice
Author Affiliations & Notes
  • James Deom
    The Dry Eye Center of North Eastern Pennsylvania, Pennsylvania, United States
    Hazleton Eye Specialists, Pennsylvania, United States
  • Shane Kannar
    Kannarr Eye Care, LLC, Pittsburg, Kansas, United States
  • Patrick Vollmer
    Vita Eye Clinic, North Carolina, United States
    Synvenio Group, North Carolina, United States
  • Footnotes
    Commercial Relationships   James Deom Bausch & Lomb, Code C (Consultant/Contractor); Shane Kannar AbbVie (Allergan), Johnson and Johnson, Alcon, Cooper, Bausch & Lomb, Vision Source, Novartis, Osmotica, Code C (Consultant/Contractor); Patrick Vollmer None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 3968 – A0248. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      James Deom, Shane Kannar, Patrick Vollmer; Retrospective analysis of the common uses of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in clinical practice. Invest. Ophthalmol. Vis. Sci. 2022;63(7):3968 – A0248.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Use of a combination corticosteroid and antibiotic product is common in ocular inflammatory conditions for which corticosteroid therapy is indicated and there exists a risk of superficial bacterial infection. Combination loteprednol etabonate 0.5% and tobramycin 0.3% (LE/T) has been evaluated for blepharokeratoconjunctivitis in two trials, but there has been limited reporting on real-world use of this combination product. We report on the use of LE/T in our practices including prescribing patterns and outcomes.

Methods : This was a retrospective chart review conducted at 3 optometric practices in the USA. Data were collected from cases in which LE/T was used and data was recorded for the period commencing with therapy with a minimum of one follow-up visit (within 2 months). Data abstracted included patient demographics, diagnosis, LE/T dosing regimen, pre- and post-treatment ocular signs, and symptoms, intraocular (IOP) pressure measurements, adverse event (AE) reports, and visual acuity, and any notations as to resolution of baseline condition. Primary outcomes included IOP elevations and AEs.

Results : A total of 98 patient charts were extracted, and data from 87 patient charts (115 LE/T treated eyes) were included in the analysis. Mean (SD) years of age was 45.6 (19.7), most patients were white (83.9%), and just over half were female (58.6). Most eyes (94 of 115) had data for only one related follow-up visit; 20 had data for two. Common baseline conditions were conjunctival injury/corneal abrasion (25.3%), keratitis (19.5%), viral conjunctivitis (16.1%), and blepharitis/MGD (11.5%). The most common LE/T dosing regimen was one drop four times daily. Mean IOP (SD) at baseline was 15.1 (4.3) mm Hg and 15.8 (4.1) mm Hg at the first follow up visit. No adverse events were recorded, and there were no changes in visual acuity with treatment. Where recorded, most patients (88.2%) were noted as having their condition resolved or resolving at the first follow up visit.

Conclusions : LE/T appears to have been well-tolerated when used for the management of various ocular inflammatory conditions encountered in optometric practice. Most patient charts reflected the resolution of the baseline condition with the use of LE/T.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×